Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus

Sandra Lee Sessoms, J. Kovarsky

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

An uncontrolled series of 10 patients with severe systemic lupus erythematosus (SLE), resistant to or intolerant of other medications, were treated with a monthly intravenous bolus of cyclophosphamide. Nine of 10 patients experienced some beneficial results, several of which were quite dramatic and associated with substantial and protracted reductions in steroid requirement. Significant drug toxicity was noted in several patients. This therapy can be a useful therapeutic adjunct in carefully selected cases; however, we are not attempting to liberalize therapeutic indications for cyclophosphamide administration in SLE.

Original languageEnglish (US)
Pages (from-to)247-251
Number of pages5
JournalClinical and Experimental Rheumatology
Volume2
Issue number3
StatePublished - Dec 1 1984

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this